Malaysia: MDA Updates Product Classification Application System and Validity of Classification Letters

Regulatory Update | Medical Devices | October 2026

Malaysia's Medical Device Authority (MDA) has introduced further changes to its Product Classification Application System (PCAS) and issued an important update on the validity of Product Classification Letters.

Published on 30 September 2026, the announcement confirms that several PCAS enhancements take effect from 1 October 2026.

If your company needs to determine whether a product falls within Malaysia's medical-device framework before entering the market, this update is directly relevant whether you're a manufacturer, authorised representative, importer, or distributor.

What Is Product Classification in Malaysia?

Product classification is an early and essential step in Malaysia's pre-market regulatory process. The MDA uses it to determine whether a product is a medical device or a non-medical device under the Medical Device Act 2012 (Act 737).

A critical distinction: product classification is not the same as risk classification.

	Product Classification	Risk Classification
Question answered	Is this a medical device?	What risk class is this medical device?
Outcome	Determines whether the product falls within the medical-device framework	Determines applicable classification rules once it's a medical device

For international manufacturers, the outcome of product classification shapes which regulatory pathway to consider next.

From Google Form to a Fully Online System

The MDA had already moved classification applications online. From 1 August 2026, applications had to be submitted through the designated PCAS, with the previous Google Form discontinued. The goal: greater efficiency, streamlined submissions, and a more organised application experience.

The 30 September announcement builds on that transition with further PCAS enhancements starting 1 October 2026, aimed at improving the application experience and streamlining classification.

What this means in practice: make sure your teams are working from the current PCAS procedures and guidance, not older workflows. The MDA's product-classification page now lists the online system alongside updated guidance for both new applications and renewal applications.

Why Letter Validity Now Matters

The announcement also addresses the implementation of validity periods for Product Classification Letters.

This is a notable shift. Previously, MDA customer-support information indicated that a letter could remain valid as long as the product's classification status didn't change and the letter carried no expiry date.

A defined validity framework changes how companies should manage these documents over the long term. MDA's resources now include separate procedures for new applications and renewals, meaning companies need to actively monitor the status of their classification documentation, especially across multiple products.

Who Should Pay Attention?

• Medical-device manufacturers planning to enter Malaysia.

• Foreign manufacturers working with Malaysian authorised representatives

• Importers and distributors assessing the regulatory status of products

• Regulatory affairs teams managing classification documentation

• Companies with existing Product Classification Letters

• Businesses introducing new or modified healthcare products to the Malaysian market

  
  

Where responsibility for submissions is shared between a manufacturer and a local representative, clear ownership of applications, supporting documents, and validity monitoring helps prevent regulatory gaps.

What This Means for Market Access

Product classification is often the first regulatory question a company must answer: "Is this product a medical device under Malaysian law?"

Once the answer is yes, a longer journey follows:

Product classification → Risk classification → Conformity assessment → Registration → Establishment licensing → Importation and supply → Post-market compliance

This update doesn't replace Malaysia's wider registration framework. It reinforces the importance of getting the first determination right and keeping the supporting documentation current.

What Companies Should Do Now

1. Review existing classification letters: Identify every letter you rely on and record its date and status.

2. Check current validity requirements: Verify whether existing letters remain valid under MDA's current arrangements, and whether renewal may eventually be needed.

3. Use the current online system: Prepare and submit all new applications through the designated PCAS.

4. Review the product description. Make sure intended purpose, claims, mode of action, and other key characteristics are accurately represented in your documentation.

5. Keep classification and registration separate. A classification decision is not a substitute for subsequent risk classification, conformity assessment, or registration requirements.

6. Monitor MDA updates. Keep tracking announcements and guidance as the online system develops, and the validity framework is implemented.

ARQon Insight

This update highlights a point that's easy to overlook in international market access: regulatory compliance begins before product registration.

Determining whether a product falls within the medical-device framework is a critical first step in building the right strategy. But a classification decision isn't the end of the journey; companies need to understand what the outcome means for the next stage, and keep their documentation current throughout the product lifecycle.

The shift to a more structured online process also underscores the value of clear internal regulatory records, particularly when activities run through local authorised representatives or market-access partners.

Treat Classification as an Ongoing Process

Rather than obtaining a classification letter once and filing it away, companies can build classification status into their wider regulatory-maintenance programme by tracking:

• Classification-letter validity

• Product changes

• Changes to intended purpose or claims

• Changes in regulatory interpretation

• Registration requirements

• Local representative responsibilities

• Relevant MDA announcements and guidance

• 
  

This approach helps surface potential issues earlier and reduces the risk of relying on outdated documentation.

Key Takeaway

Malaysia's MDA continues to modernise its product-classification process, with PCAS enhancements effective 1 October 2026 following the move to a fully online system. Combined with the new validity requirements for classification letters, companies should pay closer attention to the lifecycle of their classification documentation.

The message is straightforward:

Know your product. Confirm its regulatory status. Keep your classification documentation current.

A strong market-access strategy begins with understanding which regulatory pathway applies to your product.

How ARQon Can Support You

ARQon supports healthcare and life-science companies with regulatory intelligence and market-access activities across international markets, including:

• Regulatory intelligence and monitoring

• Market-entry strategy

• Product regulatory pathway assessment

• Medical-device registration support

• Regulatory documentation planning

• Regulatory gap analysis

• Local market-access coordination

• Ongoing regulatory monitoring

  
  

Stay Ahead. Stay Compliant. Stay Informed. With ARQon Regulatory Intelligence.

Source

Malaysia Medical Device Authority (MDA): Product Classification Application System and Product Classification Letter validity update, 30 September 2026.